Phase 2 and 3 Combination Designs to Accelerate Drug Development
加速药物开发的二期与三期联合设计AI 解读 ↓
← 返回论文列表与筛选
阅读说明
本页整理公开书目信息，不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成，未完成全文核验，可能有误；具体假设、证明与结论请核对原文。摘要保留来源文本，未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要；缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录，不合计多个记录；关联记录可能包含正式发表版本，不等于此版本单独引用。缺失不视为零，引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配，同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列，再参考通用方法与发表日期。
分类依据与纠错
AI 根据所提供的论文材料归类：摘要属于临床试验自适应设计与剂量检验，未明确讨论所列经济计量因果推断或其他细分方法。
反馈分类问题正在核对关联版本…
代码、数据与补充材料
正在核对对应版本的资源…
关注这篇论文的作者
加速药物开发的二期与三期联合设计
- 研究问题
- 如何把二期和三期试验合并为两阶段自适应设计，在筛选剂量及调整样本量后保持统计有效性并识别最低有效剂量？
- 方法与思路
- 作者先按短期安全性和疗效筛选剂量，再调整样本量并选择趋势统计量，最终合并两阶段长期临床终点的证据。
- 材料陈述的贡献
- 摘要称第二阶段适应规则无需预先规定即可保持试验有效性，并主张设计可维持稳健功效、减少患者数和所需时间。
- 阅读关注点
- 应核对适应规则可变更的准确范围、阶段间证据合并与错误率控制条件，以及长期随访、剂量识别和功效评价。
- 阅读边界
- OpenAlex索引未注明稿件版本；摘要未说明有效性保证的条件及效率比较数值，不能把规则无需预定解释为任意调整均有效。
原文摘要
For late-stage clinical development, we propose combining phase 2 and 3 trials via a two-stage adaptive design. In the first stage, short-term safety and efficacy are examined, after which low doses that lack efficacy and high doses that cause safety concerns are eliminated from further evaluation. The trial continues to the second stage with doses that are not eliminated. For the second stage, the required sample size is adjusted to maintain power. All patients, including those enrolled in the first stage, are evaluated using a clinical endpoint requiring a longer follow-up. For the second stage, trend statistics are adaptively chosen based on the estimated dose-response curve in the clinical endpoint of the first-stage patients. At the end of the trial, pairwise statistics for the first stage and adaptive trend statistics for the second stage of the clinical endpoint are combined to establish dose-response and to identify the lowest effective dose. A notable feature of our proposed approach is that the adaptation rule governing dose selection, sample size calculation, and derivation of test statistics for the second stage need not be specified in advance to maintain the validity of the trial. The phase 2/3 combination design is effective in achieving robust statistical power and is also efficient, because the number of patients and time needed are substantially reduced.